# US 2006/0079492 A1 · Compositions and treatment methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0079492 A1
- Document ID: US20060079492A1
- Status: Published application
- Kind: A1
- Application number: 11/234,675
- Filed: 2005-09-23
- Published: 2006-04-13
- Earliest claimed: 1999-10-25
- Inventors: Clarence Ahlem; Christopher Reading; James Frincke; Dwight Stickney; Henry Lardy; Padma Marwah; Ashok Marwah; Patrick Prendergast
- Web page: https://patentgrep.com/patent/US20060079492A1

## CPC

- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 31/12: Antivirals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

## Claims

### Claim 1

A parenteral formulation comprising castor oil and one, two, three or more excipients other than castor oil, and (2) a compound having the structure
wherein,
R1 is —H, —OH, —SH, ═O, ═S, ester, ether, thioester or thioether;
R2 is —H, —OH, —SH, ═O, ═S, optionally substituted alkyl, ester, ether, thioester or thioether;
R3 is —H, —F, —Cl, —Br, —I, —OH, —SH, ═O, ═S, optionally substituted alkyl, ester, ether, thioester or thioether;
one R4 is —OH, —SH, ═O, ═S, ester, ether, thioester or thioether;
the other R4 is —H or optionally substituted alkyl;
R5 is —H, —CH2OH or —CH3;
R6 is —H, —CH2OH or —CH3;
R7 is —C(R10)2—, —C(R10)2—C(R10)2—, —C(R10)2—C(R10)2—C(R10)2—, —C(R10)2—O—C(R10)2—, —C(R10)2—S—C(R10)2—, —C(R10)2—NRPR—C(R10)2—, —O—, —O—C(R10)2—, —S—, —S—C(R10)2—, —NRPR— or —NRPR—C(R10)2—;
R8 and R9 independently are —C(R10)2—, —C(R10)2—C(R10)2—, —O—, —O—C(R10)2—, —S—, —S—C(R10)2—, —NRPR— or —NRPR—C(R10)2—, or one or both of R8 or R9 independently are absent, leaving a 5-membered ring;
R10 independently are —H, —F, —Cl, —Br, —I, —OH, —SH, ═O, ═S, optionally substituted alkyl, ester, ether, thioester or thioether; and
RPR independently is —H or a protecting group, wherein the parenteral formulation contains less than about 0.3% v/v water.

### Claim 2 (depends on 1)

The parenteral formulation of claim 1 wherein the excipients are selected from the group consisting of propylene glycol, PEG100, PEG200, PEG300, PEG400 and benzyl benzoate.

### Claim 3 (depends on 1)

The parenteral formulation of claim 1 wherein the parenteral formulation contains less than 0.2% v/v water.

### Claim 4 (depends on 1)

The parenteral formulation of claim 1 wherein the parenteral formulation contains one excipient other than castor oil, which excipient is benzyl benzoate.

### Claim 5 (depends on 4)

The parenteral formulation of claim 4 wherein R7, R8 and R9 independently are —CH2, —O—, —S—, —NH—, or —C(R10)2—.

### Claim 6 (depends on 5)

The parenteral formulation of claim 5 wherein the compound has the structure

### Claim 7 (depends on 5)

The parenteral formulation of claim 5 wherein the compound has the structure

### Claim 8 (depends on 5)

The parenteral formulation of claim 5 wherein the compound has the structure
wherein R4 is —OH or a C2-20 ester.

### Claim 9 (depends on 8)

The parenteral formulation of claim 8 wherein the C2-20 ester is —O—C(O)—C1-C8 optionally substituted alkyl, —O—CH(OH)—C1-C8 optionally substituted alkyl, —O—C(O)—(CH2)n —(CHCH3)m—(CH2)o—CH3 or —O—C(O)—(CH2)n—(CHC2H5)m—(CH2)o—CH3 where n, m and o independently are 0, 1, 2, 3, 4, 5, 6, 7 or 8.

### Claim 10 (depends on 8)

The parenteral formulation of claim 8 wherein the C2-20 ester is —O—C(O)—CH3, —O—C(O)—CH2CH3, —O—C(O)—CH2CH2CH3, —O—C(O)—(CH2)5CH3, —O—C(O)CH2NH2, —O—C(O)C(CH3)H—NH2, —O—C(O)C(CH2C6H5)H—NH2, —O—C(O)—CF3, —O—C(O)—CH2CF3, —O—C(O)—(CH2)3CF3, —O—C(O)—CH2—OH, —O—C(O)—(CH2)n—(CHCH3)m—(CH2)n—CH3 or —O—C(O)—(CH2)n—(CHC2H5)m—(CH2)o—CH3 where n is 5, 6, 7 or 8, m is 0 and o is 3, 4, 5, 6, 7 or 8.

### Claim 11 (depends on 10)

The parenteral formulation of claim 10 wherein the C2-20 ester is —O—C(O)—CH3, —O—C(O)—(CH2)5CH3 or —O—C(O)—(CH2)n—CHC2H5)m—(CH2)n—CH3 where n is 5, m is 0 and o is 4 and wherein the parenteral formulation contains one excipient other than castor oil, which excipient is benzyl benzoate.

### Claim 12 (depends on 1)

A method to treat or prevent the side-effects of radiation or chemotherapy in a human comprising administering about 4-40 mg/kg/day of the compound of claim 1 in the parenteral formulation of claim 1, wherein the parenteral formulation is optionally administered by intramuscular injection.

### Claim 13 (depends on 12)

The method of claim 12 wherein the parenteral formulation is administered for 2, 3, 4, 5, 6 or 7 consecutive days, optionally followed by (1) not administering the parenteral formulation for about 14, 28, 42, 56 or 84 consecutive days, (2) administering the parenteral formulation 2, 3, 4, 5, 6 or 7 consecutive days and (3) repeating steps (1) and (2) 0, 1, 2, 3 or more times.

### Claim 14 (depends on 13)

The method of claim 13 wherein the chemotherapy is a glucocorticoid therapy or wherein the side-effects of the radiation are delayed effects of radiation.

### Claim 15 (depends on 1, 12)

The method of claim 12 wherein the daily dosage of the compound of claim 1 is about 200 mg/day, about 400 mg/day, about 500 mg/day or about 1500 mg/day.

### Claim 16 (depends on 1)

A method to treat hypogonadism in a human in need thereof comprising administering about 4-40 mg/kg/day of the compound of claim 1 in the parenteral formulation of claim 1.

### Claim 17 (depends on 16)

The method of claim 16 wherein the compound has the structure
wherein R4 is —OH or a C2-20 ester, optionally selected from the group consisting of —O—C(O)—CH3, —O—C(O)—CH2CH3, —O—C(O)—CH2CH2CH3, —O—C(O)—(CH2)5CH3, —O—C(O)CH2NH2, —O—C(O)C(CH3)H—NH2, —O—C(O)C(CH2C6H5)H—NH2, —O—C(O)—CF3, —O—C(O)—CH2CF3, —O—C(O)—(CH2)3CF3 and —O—C(O)—CH2—OH.

### Claim 18 (depends on 17)

The method of claim 17 wherein the parenteral formulation is administered for 2, 3, 4, 5, 6 or 7 consecutive days, optionally followed by (1) not administering the parenteral formulation for about 14, 28, 42, 56 or 84 consecutive days, (2) administering the parenteral formulation 2, 3, 4, 5, 6 or 7 consecutive days and (3) repeating steps (1) and (2) 0, 1, 2, 3 or more times.

### Claim 19 (depends on 17)

The method of claim 17 wherein the C2-20 ester is —O—C(O)—C1-C8 optionally substituted alkyl, —O—CH(OH)—C1-C8 optionally substituted alkyl, —O—C(O)—(CH2)n—(CHCH3)m(CH2)o—CH3 or —O—C(O)—(CH2)n—(CHC2H5)m—(CH2)o—CH3 where n, m and o independently are 0, 1, 2, 3, 4, 5, 6, 7 or 8.

### Claim 20 (depends on 19)

The method of claim 19 wherein the C2-20 ester is —O—C(O)—CH3, —O—C(O)—(CH2)5CH3 or —O—C(O)—(CH2)n—(CHC2H5)m—(CH2)o—CH3 where n is 5, m is 0 and o is 4, wherein the parenteral formulation is optionally administered by intramuscular injection and wherein the parenteral formulation contains one excipient other than castor oil, which excipient is benzyl benzoate.

### Claim 21

A compound of formula V
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, wherein
(a) R1 and R2 are each independently selected from the group consisting of a hydrogen atom and a glucuronide group having the formula
wherein (i) R7 is an alkyl ester wherein the alkyl moiety is optionally substituted, and (ii) R8, R9 and R10 are each —OR14, wherein R14 is a hydrogen atom or a protected hydroxy, optionally substituted alkyl, cycloalkyl; and (iii) at least one of R1 or R2 is not hydrogen;
(b) R5 and R6 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, and a protected hydroxy; or R5 and R6 taken together are a ketone group (═O); and
R12 and R13 are each independently selected from the group consisting of a hydrogen atom, optionally substituted alkyl, hydroxy, and a protected hydroxy.
